Linked Life Data

237849

Source:http://linkedlifedata.com/resource/pubmed/id/237849

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1975-10-10
pubmed:abstractText
The new benzodiazepine bromazepam (Ro 5-3350, Lexotan) was compared with diazepam in a double-blind, crossover trial on 30 patients with prolonged anxiety symptoms. Each drug was given for 3 weeks in a dose of 5 mg t.d.s. Bromazepam proved to be statistically significantly superior to diazepam when evaluated through patients' preferences. Fourteen patients preferred bromazepam to diazepam and four the opposite. Three cases were tied. Nine patients had to be withdrawn from the evaluation, which may create bias. A plea is made for further controlled clinical trials on bromazepam, in particular in obsessive and phobic neurosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0020-8272
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-8
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
A comparison between bromazepam (Ro 5-3350, Lexotan) and diazepam (Valium) in anxiety neurosis. A controlled, double-blind clinical trial.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial